Saturday 21 December 2024
Internal Reference Number: FOI_7467
Date Request Received: 05/10/2023 00:00:00
Date Request Replied To: 24/10/2023 00:00:00
This response was sent via: By Email
Request Summary: Biologic medicines in gastroenterology
Request Category: Companies
| Question Number 1: How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab • Vedolizumab | |
| Answer To Question 1: • Adalimumab – Humira 7 • Adalimumab Biosimilar 72 • Filgotinib 15 • Golimumab <5 • Infliximab – Remicade 23 • Infliximab Biosimilar 277 • Mirikizumab 0 • Ozanimod 0 • Risankizumab 0 • Tofacitinib <5 • Upadacitinib 5 • Ustekinumab 73 • Vedolizumab 79 | |
| Question Number 2: If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab • Vedolizumab | |
| Answer To Question 2: • Adalimumab - Humira 6 • Adalimumab Biosimilar <5 • Filgotinib 6 • Golimumab <5 • Infliximab - Remicade <5 • Infliximab Biosimilar 57 • Mirikizumab 0 • Ozanimod 0 • Risankizumab 0 • Tofacitinib <5 • Upadacitinib <5 • Ustekinumab 8 • Vedolizumab 46 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
